Skip to main content
OpenTrials
Completed

NCT Number: NCT07126938

Alcohol Impairment Detection in Healthy Adult Users With the Gaize Device

This study evaluates the effectiveness of the Gaize virtual reality headset as a non-invasive tool for detecting alcohol-related impairment through ophthalmic and neurological indicators. A total of 80 participants, evenly divided into an experimental (alcohol-consuming) and control (non-alcohol consuming) group, underwent baseline and post-consumption ocular assessments using the device. These assessments included: Lack of Smooth Pursuit, Horizontal Gaze Nystagmus at Maximum Deviation, Horizontal Gaze Nystagmus with Onset Prior to 45-Degrees, Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. The Gaize headset measured gaze vector and pupil size at 90 hertz per eye.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged between 21 and 45, having given written informed consent to participate in the research trial and certifying that they do not intend to drive post discharge. We will consider extending the observation period based on individual participants' alcohol consumption.
  • Having used alcohol at least one time prior.
  • Having experienced impairment too severe to allow for safe operation of a vehicle or work from alcohol use.
  • Planning to drink alcohol during their time at the study location.
  • Without any history of severe reactions or allergy to alcohol.
  • Having access to legal alcohol.
  • Normal or corrected to normal vision using either glasses or contact lenses, or surgery.

Exclusion criteria

  • Enrolled in, or participated in another clinical trial within 30 days before the study
  • Having a prosthetic eye, blindness, or vision not corrected to normal.
  • Severe reactions or allergy to Alcohol. Participants with a history of severe adverse reactions to alcohol (e.g., allergies, intolerances, or medical conditions worsened by alcohol) are excluded.
  • Certain Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. A detailed list of such conditions and medications will be provided to potential participants during the screening process.
  • Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with alcohol consumption during pregnancy.
  • History of Severe Motion Sickness: Participants with a history of severe motion sickness in virtual reality environments may be excluded, as they may not tolerate the virtual reality headset well.
  • Individuals who have driven a vehicle (car, truck, bicycle, etc.) to the study location will not be eligible for participation.

Treatment and study plan

alcoholic beverage

Drug

Participants in the experimental group consumed self-selected amounts of alcohol, monitored by study staff to ensure safety and compliance with protocol guidelines. Participants then filled out the remainder of the general health questionnaire, including how many drinks they consumed, and whether or not they feel too impaired to drive a vehicle or go to work.

Other names: Alcohol, Ethanol

Primary outcomes

  1. Alcohol-Associated Ocular Impairments

    Time frame: 1 hour after alcohol consumption

    Number of participants and measurement of Lack of Smooth Pursuit, Horizontal Gaze Nystagmus at Maximum Deviation, Horizontal Gaze Nystagmus with Onset Prior to 45-Degrees, and Vertical Gaze Nystagmus were evaluated before and after alcohol consumption.

Secondary outcomes

  1. Non-Alcohol Associated Ocular Impairments

    Time frame: 1 hour after Alcohol consumption

    Number of participants and measurement of Lack of Convergence, and Pupillary Rebound Dilation were evaluated before and after alcohol consumption.

Sponsors and collaborators

Lead sponsor

Gaize

Industry

Registry information

Official study title

An Observational Study to Facilitate the Development of an Alcohol Impairment Detection Device in Healthy Adult Alcohol Users

Acronym: AAI

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 17, 2025
Registry last updated
Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.